We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Resolve Therapeutics announced positive results from the Phase II study of RSLV-132 (Study 132-04), an investigational treatment for primary Sjögren’s syndrome (pSS).